{"id":6291,"date":"2019-10-30T15:40:49","date_gmt":"2019-10-30T10:10:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6291"},"modified":"2025-05-08T12:08:32","modified_gmt":"2025-05-08T06:38:32","slug":"geographic-atrophy-therapy-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market","title":{"rendered":"Geographic Atrophy Treatment Market: Novel Therapies to Enter the Market"},"content":{"rendered":"\n

Geographic atrophy (GA) is a severe, progressive, irreversible vision loss in old age people. The loss in the vision is due to the damage in a small portion of the retina at the back of the eye, known as the macula. Since the loss of vision is due to age, it is also referred to as Age-related macular degeneration. (AMD).
Geographic atrophy is an advanced form of dry age-related macular degeneration<\/a> (dry AMD). Dry AMD<\/a> is a result of deposition of small yellow substance, known as drusen, which leads to thinning and drying out of macula. <\/p>\n\n\n\n

As estimated by the Angiogenesis Foundation, Geographic Atrophy affects more than 5 million people worldwide, out of which 22% of people are over 90 years old. Talking about Japanese Geographic atrophy prevalence, around 6.6% of the patient pool was of old age population of Japan, as studied by Yoichi Sakurada et al. (2016). Furthermore, Geographic atrophy account for 26% of legal blindness cases in the UK, as per the assessment is given by the National Health Services, UK. <\/p>\n\n\n\n

Recently, a US-based\npharmaceutical company, IVERIC bio announced the results of the trials of its complement\nfactor C5 inhibitor, Zimura, indicated for reducing the rate of Geographic\natrophy in dry age-related macular degeneration patients. <\/p>\n\n\n\n

The trials showed no side-effects associated with the administration of Zimura. Zimura has a well-tolerable rate of 12 months. Moreover, there was no discontinuation of the therapy during the trial period due to any discomfort caused by the drug. However, slight complications were observed during the intravenous injection of the therapy directly into the retina. <\/p>\n\n\n\n

Other Geographic atrophy\nPipeline products <\/strong><\/h4>\n\n\n\n

With no approved standard therapies at hand and increasing Geographic atrophy prevalence, there is a dire need of novel GA therapies. These unmet needs in Geographic atrophy therapeutics market will provide the new entrants in the GA market a bright opportunity to prosper and grab a major Geographic market share. <\/p>\n\n\n\n

Geographic atrophy pipeline\nincludes as APL-2 (Apellis Pharmaceuticals), HMR59 (Hemera Biosciences),\nIONIS-FB-Lrx (Ionis Pharmaceuticals) etc. which will positively impact the\nGeographic atrophy therapy market in coming years. <\/p>\n","protected":false},"excerpt":{"rendered":"

Geographic atrophy (GA) is a severe, progressive, irreversible vision loss in old age people. The loss in the vision is due to the damage in a small portion of the retina at the back of the eye, known as the macula. Since the loss of vision is due to age, it is also referred to […]<\/p>\n","protected":false},"author":1,"featured_media":6295,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[6714,6715,15430,6713],"industry":[17225],"therapeutic_areas":[17244],"class_list":["post-6291","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-geographic-atrophy","tag-geographic-atrophy-market","tag-geographic-atrophy-pipeline","tag-geographic-atrophy-prevalence","industry-pharmaceutical","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"\nGeographic Atrophy treatment market | Geographic Atrophy emerging drugs<\/title>\n<meta name=\"description\" content=\"Increasing Geographic atrophy prevalence and no approved standard therapies in Geographic atrophy therapeutics market offer a bright opportunity to...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Geographic Atrophy treatment market | Geographic Atrophy emerging drugs\" \/>\n<meta property=\"og:description\" content=\"Increasing Geographic atrophy prevalence and no approved standard therapies in Geographic atrophy therapeutics market offer a bright opportunity to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-30T10:10:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:38:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022448\/geographic.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Geographic Atrophy treatment market | Geographic Atrophy emerging drugs","description":"Increasing Geographic atrophy prevalence and no approved standard therapies in Geographic atrophy therapeutics market offer a bright opportunity to...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market","og_locale":"en_US","og_type":"article","og_title":"Geographic Atrophy treatment market | Geographic Atrophy emerging drugs","og_description":"Increasing Geographic atrophy prevalence and no approved standard therapies in Geographic atrophy therapeutics market offer a bright opportunity to...","og_url":"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-30T10:10:49+00:00","article_modified_time":"2025-05-08T06:38:32+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022448\/geographic.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market","url":"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market","name":"Geographic Atrophy treatment market | Geographic Atrophy emerging drugs","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022448\/geographic.jpg","datePublished":"2019-10-30T10:10:49+00:00","dateModified":"2025-05-08T06:38:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Increasing Geographic atrophy prevalence and no approved standard therapies in Geographic atrophy therapeutics market offer a bright opportunity to...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-therapy-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022448\/geographic.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022448\/geographic.jpg","width":772,"height":482,"caption":"Geographic atrophy market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09022448\/geographic-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Geographic atrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Geographic atrophy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Geographic Atrophy Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Geographic atrophy prevalence<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Geographic atrophy<\/span>","<span class=\"advgb-post-tax-term\">Geographic atrophy market<\/span>","<span class=\"advgb-post-tax-term\">Geographic Atrophy Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Geographic atrophy prevalence<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Oct 30, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Oct 30, 2019 3:40 pm","modified":"Updated on May 8, 2025 12:08 pm"},"featured_img_caption":"Geographic atrophy market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6291"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6291\/revisions"}],"predecessor-version":[{"id":31912,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6291\/revisions\/31912"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6295"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6291"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6291"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}